Editorial Material
Oncology
Yu Chen, Jinming Yu, Xiangjiao Meng
Summary: This commentary emphasizes the potential of postoperative radiotherapy in patients with completely resected IIIA-N2 non-small cell lung cancer.
Article
Medicine, General & Internal
Ju-Chun Chien, Yu-Chang Hu, Yi-Ju Tsai, Yu-Ting Chien, I-Jung Feng, Yow-Ling Shiue
Summary: This study evaluated the treatment effect of post-operative radiotherapy (PORT) in patients with completely resected pN2 stage III non-small cell lung cancer (R0 pN2-stage III NSCLC) and identified predictive factors. The results showed that PORT prolongs disease-free survival (DFS) and overall survival (OS) in selected patients. Further research on predictive factors and the development of guidelines for the application of PORT are crucial.
Article
Oncology
Shih-Min Lin, Hsiu-Ying Ku, Che-Yu Hsu, Chih-Liang Wang, Gee-Chen Chang, Cheng-Shyong Chang, Tsang-Wu Liu
Summary: The study aimed to investigate the effects of the time interval between initiation of adjuvant chemotherapy and radiotherapy on survival outcomes in patients with completely resected stage IIIA pN2 non-small-cell lung cancer. The results showed that a longer interval between initiation of adjuvant chemotherapy and postoperative radiotherapy improved overall survival relative to concurrent chemoradiotherapy, with greater benefits observed in elderly patients.
Review
Oncology
Antonio Passaro, Tony S. K. Mok, Ilaria Attili, Yi-Long Wu, Masahiro Tsuboi, Filippo de Marinis, Solange Peters
Summary: Adjuvant osimertinib has revolutionized the treatment algorithm for patients with resected EGFR mutation-positive NSCLC. Further evidence driven by clinical issues will be key for further optimization of the goals of adjuvant treatment in these patients.
Article
Oncology
Hui Yang, Kunlun Wang, Shenglei Li, Yan Li, Ling Yuan
Summary: The study found that postoperative radiotherapy may improve disease-free survival of stage IIIA/N2 NSCLC patients with complete surgical resection and postoperative chemotherapy, but it does not increase overall survival. Factors such as EGFR mutation status, T stage, and type of surgery may be independent prognostic factors for disease-free survival, while the type of surgery is associated with overall survival.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Article
Oncology
Hsiu-Ying Ku, Shih-Min Lin, Chih-Liang Wang, Yuan-Ting C. Lo, Cheng-Shyong Chang, Gee-Chen Chang, Hui-Ju Ch 'ang, Tsang-Wu Liu
Summary: In patients with completely resected stage IIIA non-small cell lung cancer, those with poorly differentiated tumors and pN2 disease who received postoperative radiotherapy showed a lower risk of distant recurrence and more favorable survival outcomes.
Review
Oncology
Krisztian Sueveg, Ludwig Plasswilm, Thomas Iseli, Pawel Leskow, Galina Farina Fischer, Paul Martin Putora
Summary: The use of postoperative radiotherapy (PORT) in completely resected non-small cell lung cancer (NSCLC) with ipsilateral mediastinal lymph node involvement (pN2) is controversial. Guidelines do not recommend the routine use of PORT due to conflicting results. Future research should focus on identifying subgroups of patients who might benefit from PORT.
Article
Oncology
Anne-Laure Desage, Claire Tissot, Sophie Bayle-Bleuez, Thierry Muron, Nadine Deygas, Valerie Grangeon-Vincent, Brigitte Monange, Fatah Torche, Paul Vercherin, David Kaczmarek, Olivier Tiffet, Fabien Forest, Jean-Michel Vergnon, Wafa Bouleftour, Pierre Fournel
Summary: This retrospective study evaluated the compliance to guidelines, safety and efficacy of adjuvant chemotherapy (AC) in a less selected population of patients with non-small cell lung cancer (NSCLC). It found that AC use may differ from guidelines in real-life practice, but it can still be used safely and remains efficient among a less selected population.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Review
Oncology
Lucheng Zhu, Bing Xia, Shenglin Ma
Summary: The role of adjuvant radiotherapy in completely resected pIIIA-N2 NSCLC is controversial. Previous studies have shown that postoperative radiotherapy can reduce local recurrence and prolong disease-free survival, but recent randomized controlled trials have shown no survival benefit. We need to reassess the value of postoperative radiotherapy.
Article
Medicine, General & Internal
Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, Giovanni Natale, Vittorio Patane, Marco De Chiara, Mauro Buono, Gaetano Maria Russo, Riccardo Monti, Giovanni Balestrucci, Maria Salvarezza, Gaetano Di Guida, Emma D'Ippolito, Angelo Sangiovanni, Roberta Grassi, Ida D'Onofrio, Maria Paola Belfiore, Giovanni Cimmino, Carminia Maria Della Corte, Giovanni Vicidomini, Alfonso Fiorelli, Antonio Gambardella, Floriana Morgillo, Salvatore Cappabianca
Summary: Treatment-induced cardiac toxicity is a significant issue in NSCLC patients, with no available biomarkers in clinical practice. The Agatston score (or CAD score) is a novel and easy-to-calculate marker for quantitative analysis of calcium plaque in the coronary on CT. Our study aimed to correlate cardiac biomarkers with overall survival in NSCLC patients.
Article
Oncology
S. Novello, V Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N. J. Dickgreber, L. Irtelli, G. Wiest, V Monica, L. Porcu, C. Manegold, G. Scagliotti
Summary: This study aimed to evaluate the predictive utility of ERCC1 and TS mRNA expression levels in resected tumors. The results showed that tailored adjuvant chemotherapy in completely resected stage II-III NSCLC demonstrated a non-statistically significant trend for overall survival favoring the tailored arm, with better efficacy/toxicity ratio compared to standard chemotherapy.
ANNALS OF ONCOLOGY
(2022)
Review
Surgery
Chai Hong Rim, Won Kyung Cho, Sunmin Park, Won Sup Yoon, Dae Sik Yang
Summary: This meta-analysis confirms the oncologic role of local ablative treatment (LAT) in treating oligometastatic nonsmall cell lung cancer, with synchronous and oligopersistent disease showing more benefit than oligoprogression/recurrence disease.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Article
Medicine, General & Internal
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csoszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark McCleland, Elizabeth Bennett, Barbara Gitlitz, Heather Wakelee
Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.
Article
Oncology
Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Hong
Summary: A comparative analysis suggests that osimertinib is a more suitable adjuvant therapy than immunotherapy for completely resected EGFR-mutant NSCLC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Cardiac & Cardiovascular Systems
Jorge Humberto Rodriguez-Quintero, Mohamed K. Kamel, Rajika Jindani, Roger Zhu, Patricia Friedmann, Marc Vimolratana, Neel P. Chudgar, Brendon Stiles
Summary: The underutilization of adjuvant systemic therapy (AT) in patients with resected stage II-III NSCLC is associated with patient, institutional, and socioeconomic factors. Measures should be implemented to address these inequities, especially in light of newer treatment options that can improve survival.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2023)